FDA Opens Applications for Expedited IND Pilot to Accelerate Early Clinical Development

The FDA has announced the final design of its Expedited Investigational New Drug (IND) Pilot and opened applications through October 30, 2026. The program will pair drug sponsors with qualified research institutions (QRIs) to support IND preparation and test whether closer collaboration can shorten the path to first-in-human trials. Sponsors and prospective QRIs must apply jointly, with sponsors submitting applications; FDA expects to select 8–10 pairs initially.

Participating institutions will provide scientific expertise to support FDA review and acceptance of individual application components on a rolling basis during the pre-IND phase, rather than waiting for all components before review begins. The agency aims to identify and resolve issues earlier and reduce the risk of clinical holds during the 30-day IND review period. The pilot also encourages coordination of institutional review board review and trial-site activation alongside IND development, where appropriate.

For clinical investigators and sponsors, the initiative may help coordinate regulatory preparation and trial initiation, but the announcement provides no outcome data demonstrating shorter timelines. FDA retains full authority over whether investigations may proceed and whether clinical holds are required. Findings could inform future early-development policies, including a possible formal accreditation model for qualified institutions; such a model is not yet established.